Srinivasan Ramanuja, MD
Allergy & Immunology · Mankato, MNNPI 1720184849
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,675 of the $18,072 with a category attached, or 75.7%. AstraZeneca accounts for 84.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $15,352, more than ten times the $377 reported in 2019.
Across 118 payments — averaging $153.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Genentech USA, Inc.$1K
- Amgen$177
- Kaleo, Inc.$119
- Regeneron Healthcare Solutions, Inc.$99
- Alk-abello, Inc$96
- plus $1K from 24 others
Across 41 payments — averaging $8154.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$221K
- Sanofi US Services Inc.$70K
- Astrazeneca UK Limited$26K
- Pfizer$17K
What the payments were for
- Consulting fees$1,2157%
- Speaking & faculty fees$13,67576%
- Travel & lodging$1,0756%
- Food & beverage$2,08112%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $15,299 |
| Genentech USA, Inc. | 4 | $1,262 |
| Amgen | 12 | $177 |
| Kaleo, Inc. | 8 | $119 |
| Regeneron Healthcare Solutions, Inc. | 6 | $99 |
| Alk-abello, Inc | 1 | $96 |
| Pharming Healthcare, Inc. | 5 | $86 |
| Teva Pharmaceuticals USA, Inc. | 5 | $84 |
| CSL Behring | 3 | $68 |
| Sanofi | 4 | $64 |
| Boehringer Ingelheim | 4 | $60 |
| Biocryst US Sales Co., LLC | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Grifols USA, LLC | 4 | $56 |
| GSK | 3 | $51 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $49 |
| Novartis | 3 | $46 |
| Optinose US, Inc. | 2 | $46 |
| Ionis Pharmaceuticals, Inc. | 2 | $40 |
| Pfizer | 3 | $37 |
| Insmed, Inc. | 2 | $33 |
| Philips North America LLC | 2 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| USWM, LLC | 1 | $24 |
| Octapharma USA, Inc. | 2 | $24 |
| Axonics, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $17 |
| Incyte Corporation | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,072 in reported general payments places this provider in the 85th percentile of 57 allergy & immunology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 13 | $533,813 |
| Spiriva RespimatTiotropium Bromide | 58 | $31,503 |
| DuleraMometasone/Formoterol | 52 | $24,225 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $14,876 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $10,507 |
| Epinephrine | 41 | $10,217 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $8,372 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,352 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $7,118 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $3,189 |
| Montelukast Sodium | 175 | $2,462 |
| Fluticasone Propionate | 169 | $2,382 |
| Ventolin HfaAlbuterol Sulfate | 28 | $1,759 |
| Levocetirizine Dihydrochloride | 80 | $1,683 |
| Azelastine Hcl | 81 | $1,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $60 | $533,81313 claims |
| Boehringer IngelheimSpiriva Respimat | $60 | $31,50358 claims |
| AstraZenecaSymbicort | $15,299 | $8,37216 claims |
| GSKBreo Ellipta | $51 | $8,35223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 allergy & immunology providers in Minnesota.
Other allergy & immunology in Mankato
- Richard CrockettMankato$15
- Nicole ChaseSaint Paul$1.8M
- Jason RaaschPlymouth$153K
- Thanai PongdeeRochester$58K
- Elina JerschowRochester$45K
- Nancy OttMinneapolis$23K
- David LoweRochester$18K
- Douglas McMahonMaplewood$18K
- Niladri AichbhaumikSaint Paul$15K
- Dayne VoelkerRochester$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.